How to buy ZIOPHARM Oncology stock | $2.74

ZIOPHARM Oncology, Inc is a biotechnology business based in the US. ZIOPHARM Oncology shares (ZIOP) are listed on the NASDAQ and all prices are listed in US Dollars. ZIOPHARM Oncology employs 73 staff and has a market cap (total outstanding shares value) of USD$605.4 million.

How to buy shares in ZIOPHARM Oncology

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for ZIOPHARM Oncology. Find the stock by name or ticker symbol: ZIOP. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until ZIOPHARM Oncology reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$2.74, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of ZIOPHARM Oncology, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of ZIOPHARM Oncology. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

ZIOPHARM Oncology share price

Use our graph to track the performance of ZIOP stocks over time.

ZIOPHARM Oncology shares at a glance

• Key figures

Information last updated 2020-12-03.

Latest market close	USD$2.74
52-week range	USD$1.795 - USD$5.605
50-day moving average	USD$2.5489
200-day moving average	USD$2.8916
Wall St. target price	USD$5.93
PE ratio	4.3467
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$0.575

Buy ZIOPHARM Oncology shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy ZIOPHARM Oncology stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of ZIOPHARM Oncology, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

ZIOPHARM Oncology price performance over time

Historical closes compared with the close of $2.74 from 2020-12-09

1 week (2021-01-05)	-3.52%
1 month (2020-12-12)	N/A
3 months (2020-10-12)	-1.97%
6 months (2020-07-12)	N/A

1 year (2020-01-12)	N/A
2 years (2019-01-12)	N/A
3 years (2018-01-12)	4.36
5 years (2016-01-12)	6.27

Is ZIOPHARM Oncology under- or over-valued?

Valuing ZIOPHARM Oncology stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of ZIOPHARM Oncology's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

ZIOPHARM Oncology's P/E ratio

ZIOPHARM Oncology's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 4x. In other words, ZIOPHARM Oncology shares trade at around 4x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

ZIOPHARM Oncology financials

Gross profit TTM	USD$-38,331,000
Return on assets TTM	-32.42%
Return on equity TTM	-58.12%
Profit margin	0%
Book value	$0.681
Market capitalisation	USD$605.4 million

TTM: trailing 12 months

Shorting ZIOPHARM Oncology shares

There are currently 33.4 million ZIOPHARM Oncology shares held short by investors – that's known as ZIOPHARM Oncology's "short interest". This figure is 0.1% down from 33.5 million last month.

There are a few different ways that this level of interest in shorting ZIOPHARM Oncology shares can be evaluated.

ZIOPHARM Oncology's "short interest ratio" (SIR)

ZIOPHARM Oncology's "short interest ratio" (SIR) is the quantity of ZIOPHARM Oncology shares currently shorted divided by the average quantity of ZIOPHARM Oncology shares traded daily (recently around 1.5 million). ZIOPHARM Oncology's SIR currently stands at 22.32. In other words for every 100,000 ZIOPHARM Oncology shares traded daily on the market, roughly 22320 shares are currently held short.

However ZIOPHARM Oncology's short interest can also be evaluated against the total number of ZIOPHARM Oncology shares, or, against the total number of tradable ZIOPHARM Oncology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ZIOPHARM Oncology's short interest could be expressed as 0.16% of the outstanding shares (for every 100,000 ZIOPHARM Oncology shares in existence, roughly 160 shares are currently held short) or 0.1699% of the tradable shares (for every 100,000 tradable ZIOPHARM Oncology shares, roughly 170 shares are currently held short).

A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against ZIOPHARM Oncology.

Find out more about how you can short ZIOPHARM Oncology stock.

ZIOPHARM Oncology share dividends

We're not expecting ZIOPHARM Oncology to pay a dividend over the next 12 months.

Have ZIOPHARM Oncology's shares ever split?

ZIOPHARM Oncology's shares were split on a 1:40 basis on 24 August 2005. So if you had owned 40 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your ZIOPHARM Oncology shares – just the quantity. However, indirectly, the new 3900% higher share price could have impacted the market appetite for ZIOPHARM Oncology shares which in turn could have impacted ZIOPHARM Oncology's share price.

ZIOPHARM Oncology share price volatility

Over the last 12 months, ZIOPHARM Oncology's shares have ranged in value from as little as $1.795 up to $5.605. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ZIOPHARM Oncology's is 2.2356. This would suggest that ZIOPHARM Oncology's shares are significantly more volatile than the average for this exchange and represent a higher risk.

ZIOPHARM Oncology overview

ZIOPHARM Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells. It is developing Ad-RTS-hIL-12 plus veledimex, which is in Phase 2 clinical trial, to treat patients with recurrent glioblastoma multiforme in adults. The company is also developing chimeric antigen receptor (CAR) T-cell and T-cell receptor T-cell therapies. ZIOPHARM Oncology, Inc. has license agreement with Precigen, Inc. and MD Anderson Cancer Center; collaboration with MD Anderson targeting CD19 on malignant B cells using Sleeping Beauty platform; and research and development agreement with the National Cancer Institute to evaluate autologous peripheral blood lymphocytes, and Ares Trading S.A. The company was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Frequently asked questions

• What percentage of ZIOPHARM Oncology is owned by insiders or institutions?

  Currently 6.576% of ZIOPHARM Oncology shares are held by insiders and 55.94% by institutions.

• How many people work for ZIOPHARM Oncology?

  Latest data suggests 73 work at ZIOPHARM Oncology.

• When does the fiscal year end for ZIOPHARM Oncology?

  ZIOPHARM Oncology's fiscal year ends in December.

• Where is ZIOPHARM Oncology based?

  ZIOPHARM Oncology's address is: Parris Building 34, Boston, MA, United States, 02129

• What is ZIOPHARM Oncology's ISIN number?

  ZIOPHARM Oncology's international securities identification number is: US98973P1012

• What is ZIOPHARM Oncology's CUSIP number?

  ZIOPHARM Oncology's Committee on Uniform Securities Identification Procedures number is: 98973P101